Renlund D G, O'Connell J B, Gilbert E M, Watson F S, Bristow M R
J Heart Transplant. 1987 Mar-Apr;6(2):71-8.
Corticosteroid maintenance immunosuppression therapy was successfully discontinued in 24 of 46 patients (52%) who underwent orthotopic heart transplantation between March 8, 1985 and September 1, 1986. In the remaining 22 patients three or more rejection episodes occurred within a 4-month period, and these patients were subsequently maintained on low to moderate dosages of corticosteroids. Patients successfully withdrawn from corticosteroid maintenance (group 1) have remained rejection free for 208 +/- 33 days (mean +/- SEM) after discontinuation of the maintenance therapy with corticosteroids, and their immunosuppression therapy has consisted only of cyclosporine (mean overall cumulative dose 198 +/- 11 mg/m2/day [5.17 +/- 0.35 mg/kg/day]) and azathioprine (mean overall cumulative dose 67.7 +/- 5.4 mg/m2/day [1.74 +/- 0.13 mg/kg/day]), with the most recent serum cyclosporine level and white blood cell count being 146 +/- 10 ng/ml and 5400 +/- 200/microliters, respectively. In contrast to the patients who continue to require maintenance therapy with corticosteroids (group 2), group 1 patients developed their first episode of rejection later (46.8 +/- 8.3 days versus 25.4 +/- 6.1 days, p = 0.040) and reject less frequently during the first 4 months after transplantation (1.7 +/- 0.2 episodes versus 2.6 +/- 0.2 episodes, p = 0.005) as well as during the entire follow-up period (0.21 +/- 0.02 episodes/month versus 0.30 +/- 0.02 episodes/month, p = 0.005). The decreased propensity to reject and subsequent corticosteroid discontinuation resulted in a decreased cumulative dose of corticosteroids in group 1 patients (10.9 +/- 1.9 mg prednisone equivalent/m2/day [0.28 +/- 0.04 mg/kg/day] versus 17.0 +/- 1.2 mg prednisone equivalent/m2/day [0.42 +/- 0.04 mg/kg/day], p = 0.011 [p = 0.026]).(ABSTRACT TRUNCATED AT 250 WORDS)
在1985年3月8日至1986年9月1日接受原位心脏移植的46例患者中,24例(52%)成功停用了皮质类固醇维持免疫抑制治疗。其余22例患者在4个月内发生了3次或更多次排斥反应,随后这些患者继续接受低至中等剂量的皮质类固醇维持治疗。成功停用皮质类固醇维持治疗的患者(第1组)在停用皮质类固醇维持治疗后208±33天(平均值±标准误)未发生排斥反应,他们的免疫抑制治疗仅包括环孢素(平均总累积剂量198±11mg/m²/天[5.17±0.35mg/kg/天])和硫唑嘌呤(平均总累积剂量67.7±5.4mg/m²/天[1.74±0.13mg/kg/天]),最近一次血清环孢素水平和白细胞计数分别为146±10ng/ml和5400±200/微升。与继续需要皮质类固醇维持治疗的患者(第2组)相比,第1组患者首次发生排斥反应的时间较晚(46.8±8.3天对25.4±6.1天,p = 0.040),并且在移植后的前4个月内排斥反应发生频率较低(1.7±0.2次对2.6±0.2次,p = 0.005),在整个随访期间也是如此(0.21±0.02次/月对0.30±0.02次/月,p = 0.005)。排斥反应倾向降低及随后停用皮质类固醇导致第1组患者皮质类固醇累积剂量减少(泼尼松等效剂量10.9±1.9mg/m²/天[0.28±0.04mg/kg/天]对17.0±1.2mg泼尼松等效剂量/m²/天[0.42±0.04mg/kg/天],p = 0.011[p = 0.026])。(摘要截短至250字)